Passage Bio, Inc. - חוב לטווח קצר של החברה PASG

Passage Bio, Inc. (PASG) aims to secure a dominant position in the treatment of rare CNS pathologies by developing AAV vectors. The strategy relies on a partnership with the University of Pennsylvania and the implementation of robotic systems in laboratories. The short-term borrowing metric reflects obligations of up to one year, with the indicator currently standing at 0.00, which helps assess the issuer's current credit stability.

To assess the fundamental stability of Passage Bio, Inc. (PASG), it is essential to weigh its long-term potential to monopolize the orphan gene therapy market against its current liquidity. By analyzing short-term debt financing, an investor determines the volume of obligations maturing within one year, which allows for an assessment of the developer's solvency and the risk of cash flow gaps in the absence of operational cash flow.